Skip to main content
    W

    Whitehawk Therapeutics, Inc. (WHWK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.01
    -0.05 (-1.63%)

    Market Cap: $180.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Whitehawk Therapeutics, Inc. (WHWK) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Whitehawk Therapeutics are Protara Therapeutics (TARA), NeOnc Technologies Holdings, Inc. Common Stock (NTHI) and Invivyd (IVVD). By market cap, Whitehawk Therapeutics ranks 6th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.

    Peer Comparison

    WHWK's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Whitehawk Therapeutics (WHWK)$180.57MN/AN/A0.0%N/A-100.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Foghorn Therapeutics Inc (FHTX)$124.12M40.1x1.1x8.4%N/A925.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Humacyte Inc (HUMA)$155.12MN/A62.6x0.0%-60.5%36.5%0.00%
    Inhibikase Therapeutics Inc (IKT)$213.21MN/AN/A0.0%N/A-100.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    OUTLOOK THERAPEUTICS INC (OTLK)$100.54MN/AN/A0.0%-776.9%-99.4%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Peer median$163.68M40.1x4.9x0.0%-60.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Whitehawk Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    Foghorn Therapeutics Inc (FHTX)
    Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within...
    FHTX competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Humacyte Inc (HUMA)
    Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine...
    HUMA competitors
    Inhibikase Therapeutics Inc (IKT)
    Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside...
    IKT competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    OUTLOOK THERAPEUTICS INC (OTLK)
    Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic...
    OTLK competitors
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors

    Frequently Asked Questions About WHWK

    Who are Whitehawk Therapeutics' main competitors?

    The companies most similar to Whitehawk Therapeutics include Protara Therapeutics (TARA), NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Invivyd (IVVD), Compass Therapeutics (CMPX) and Foghorn Therapeutics (FHTX), listed from the closest match.

    Who is Whitehawk Therapeutics' biggest competitor?

    Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Protara Therapeutics (TARA) is the closest match by business profile, size, sector and industry.

    How does WHWK stock compare with its competitors?

    WHWK's net margin is 0.0% against a peer median of 0.0%.

    Which of Whitehawk Therapeutics' competitors pays a higher dividend?

    Whitehawk Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Whitehawk Therapeutics bigger than its competitors?

    No. Whitehawk Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.